Subhashie Sarathkumara, MD
Neurology · Austin, TXNPI 1215190244
Payments from drug & device makers
Across 509 payments — averaging $507.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$130K
- Teva Pharmaceuticals USA, Inc.$90K
- Acorda Therapeutics, Inc$19K
- Sunovion Pharmaceuticals Inc.$15K
- Boston Scientific$1K
- Acadia Pharmaceuticals Inc$603
- plus $3K from 22 others
Across 12 payments — averaging $79.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$958
What the payments were for
- Consulting fees$6,1855%
- Speaking & faculty fees$104,11081%
- Travel & lodging$9,0827%
- Food & beverage$9,6898%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $130,197 |
| Teva Pharmaceuticals USA, Inc. | 120 | $89,698 |
| Acorda Therapeutics, Inc | 37 | $19,034 |
| Sunovion Pharmaceuticals Inc. | 32 | $14,613 |
| Boston Scientific | 59 | $1,320 |
| Acadia Pharmaceuticals Inc | 42 | $603 |
| Medtronic(2 entities) | 12 | $431 |
| Neurocrine Biosciences, Inc. | 31 | $424 |
| Abbott | 10 | $256 |
| Kyowa Kirin, Inc. | 12 | $246 |
| MDD US Operations, LLC | 13 | $245 |
| Adamas Pharmaceuticals, Inc. | 7 | $152 |
| Merz Pharmaceuticals, LLC | 6 | $146 |
| Amneal Pharmaceuticals LLC | 9 | $144 |
| GE HealthCare | 10 | $143 |
| Arbor Pharmaceuticals, Inc. | 9 | $135 |
| Avion Pharmaceuticals | 5 | $93 |
| UCB, Inc. | 5 | $73 |
| Amgen | 3 | $70 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| Eisai Inc. | 3 | $56 |
| Novartis | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Merz North America, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $26 |
| Insightec,inc | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$73,276
- INBRIJA$18,328
- Austedo XR$15,189
- LATUDA$9,014
- KYNMOBI$5,000
- SPECTRA WAVEWRITER$510
- ACTIVA$214
- Duopa$113
- VERCISE$104
How this compares
$258,334 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 62 | $496,729 |
| AustedoDeutetrabenazine | 45 | $404,774 |
| NuplazidPimavanserin Tartrate | 56 | $344,985 |
| RytaryCarbidopa/Levodopa | 192 | $267,396 |
| Droxidopa | 18 | $138,480 |
| GocovriAmantadine Hcl | 49 | $119,941 |
| InbrijaLevodopa | 16 | $47,049 |
| HorizantGabapentin Enacarbil | 14 | $31,558 |
| NeuproRotigotine | 16 | $29,248 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $28,612 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 769 | $24,903 |
| OngentysOpicapone | 26 | $21,712 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 324 | $11,920 |
| LinzessLinaclotide | 13 | $6,589 |
| Rasagiline Mesylate | 50 | $5,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $89,698 | $901,503107 claims |
| Acadia Pharmaceuticals IncNuplazid | $603 | $344,98556 claims |
| Amneal Pharmaceuticals LLCRytary | $144 | $267,396192 claims |
| MDD US Operations, LLCGocovri | $245 | $119,94149 claims |
| Acorda Therapeutics, IncInbrija | $19,034 | $47,04916 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $135 | $31,55814 claims |
| UCB, Inc.Neupro | $73 | $29,24816 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $65 | $28,61214 claims |
| Neurocrine Biosciences, Inc.Ongentys | $424 | $21,71226 claims |
| AbbVieLinzess | $130,197 | $6,58913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Austin
- Esther MelamedAustin$593K
- Sami AboumatarAustin$593K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.